.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Physicians widely prescribe Gliclazide as a cornerstone sulfonylurea for the management of type 2 diabetes mellitus. However, its poor aqueous solubility often limits its therapeutic efficacy and bioavailability. Recent pharmaceutical advancements in gliclazide dissolution enhancement now utilize room-temperature atomic layer deposition (ALD) to address these formulation challenges. By applying ultra-thin SiO2 films directly to drug particles, researchers have successfully transformed the drug's physical properties for better clinical performance.
The core problem with gliclazide lies in its strongly hydrophobic nature. This characteristic prevents the drug particles from dispersing effectively in aqueous media. Consequently, patients may experience inconsistent absorption and varying drug levels in the bloodstream. However, the application of ultra-thin silica coatings through ALD changes the particle surface to a highly hydrophilic state. This critical modification promotes a highly dispersed state in the gastrointestinal environment. Furthermore, the SiO2 coating significantly accelerates the dissolution process. Notably, engineers can now tailor the drug's release kinetics by simply adjusting the coating thickness. Therefore, this technology provides a precise, multipurpose design for controlled drug delivery.
Moreover, this surface engineering approach aligns perfectly with existing pharmaceutical manufacturing standards. Since many modern medications face similar solubility issues, ALD presents a versatile solution for the industry. It not only overcomes traditional solubility limitations but also optimizes the release profiles of other poorly soluble chemical entities. Thus, healthcare providers can eventually expect more predictable and optimized therapeutic outcomes with these advanced gliclazide formulations. This innovation represents a promising pathway for improving the bioavailability of essential antidiabetic therapies.
Atomic layer deposition applies a nanometer-scale SiO2 layer that converts the hydrophobic drug surface into a hydrophilic one. This change ensures better dispersion and a faster dissolution rate in aqueous environments like the digestive tract.
Tunable dissolution allows researchers to control exactly how fast the medication enters the circulation. By varying the SiO2 coating thickness, manufacturers can create tailored drug release kinetics to suit different therapeutic needs.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Cao VP et al. Tunable dissolution of poorly soluble gliclazide by surface coating via room-temperature atomic layer deposition. J Chem Phys. 2026 Jun 14. doi: undefined. PMID: 42283359.
2. Das S et al. The Role of Gliclazide as a Preferred Modern Sulfonylurea. Curr Trends Intern Med. 2025 May 23. doi: 10.29011/2638-003X.100243.
3. Ibrahim BA et al. Enhancing gliclazide solubility using solid dispersions with carboxymethyl chitosan and polyvinylpyrrolidone K30 as polymeric carriers. Drug Dev Ind Pharm. 2025 May 28. doi: 10.1080/03639045.2025.2359401.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study highlights the use of room-temperature atomic layer deposition (ALD) to apply ultra-thin SiO2 films to gliclazide. This process enhances the drug's wettability and provides a tunable dissolution profile, promising improved bioavailability for this widely used antidiabetic medication.
4 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
